This CME/CE-certified activity will explore current therapies for dyslipidemia and the challenges faced in the clinic when treating to targets.

The management of patients with dyslipidemia continues to focus on the use of statin therapy. While current agents are effective, many patients fail to reach current treatment targets for LDL-C. Moreover, there is evidence that lower LDL-C targets may be associated with improved outcomes; however, these are not readily achieved with current agents. Failure to reach targets may be due to the efficacy of current treatments and also a number of physician and patient-related factors. The opportunities for improving outcomes in these patients will be reviewed.

Importantly, research is continuing into novel treatments, including alternative targets in the cholesterol synthesis pathway, for example, the inhibition of squalene synthase. In addition, increasing HDL-C remains an opportunity, despite the recent disappointments with the CETP inhibitors. Some of these novel therapies are anticipated to reach the clinic in the near future and these will be highlighted.

This program is based on a symposium presented in Orlando, November 2007.

Attend the symposium on-line, listening to an audio recording of the expert faculty as you watch their slide presentations. Alternatively, print off the slides and a transcript of the presentations to study at your leisure.

CME/CE credits are available on submission of a completed evalaution form and post-test.